Price Alert

PureTech Health (PRTC)

NASDAQ: PRTC · Real-Time Price · USD

17.30

-0.70 (-3.89%)

At close: Oct 16, 2025, 3:59 PM

17.11

-1.10%

After-hours: Oct 16, 2025, 06:08 PM EDT

-3.89% (1D)

Bid	17
Market Cap	418.11M
Revenue (ttm)	5.88M
Net Income (ttm)	50.68M
EPS (ttm)	1.7
PE Ratio (ttm)	10.18
Forward PE	-4.16
Analyst	Buy
Dividends	n/a

Ask	18.4
Volume	361
Avg. Volume (20D)	3,960
Open	17.71
Previous Close	18.00
Day's Range	17.30 - 17.71
52-Week Range	13.30 - 24.99
Beta	0.81
Ex-Dividend Date	n/a

About PRTC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PRTC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PRTC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

PureTech Health is scheduled to release its earnings on Apr 29, 2026, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

10 months ago

+8.85%

PureTech Health shares are trading higher after th... Unlock content with Pro Subscription

News

2 weeks ago · businesswire.com

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.

1 month ago · zacks.com

What Makes PureTech Health (PRTC) a New Buy Stock

PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · businesswire.com

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.

1 month ago · businesswire.com

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.

2 months ago · businesswire.com

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

2 months ago · businesswire.com

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint.